[{"id":"35e34361-ae0b-4c69-8d47-4171b1f9736a","acronym":"PROMENADE","url":"https://clinicaltrials.gov/study/NCT04997317","created_at":"2021-08-09T13:53:17.457Z","updated_at":"2024-07-02T16:35:15.190Z","phase":"Phase 1","brief_title":"Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide","source_id_and_acronym":"NCT04997317 - PROMENADE","lead_sponsor":"University Hospital, Basel, Switzerland","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SOMther (lutetium-177 DOTA satoreotide) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/21/2021","start_date":" 04/21/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-12"}]